SIGA Technologies 2025 revenue falls

Reuters03-11

SIGA Technologies 2025 revenue falls

Overview

U.S. infectious disease drugmaker's 2025 revenue and net income fell sharply from prior year
In January 2026, company received $13 mln international order for oral TPOXX

Outlook

SIGA received $13 mln international procurement order for oral TPOXX to be delivered in 2026
Company expects CHMP to confirm positive benefit-risk balance for tecovirimat in March 2026
SIGA focused on securing new procurement contracts with governments to support future revenues

Result Drivers

U.S. PROCUREMENT DROP - Co attributed lower 2025 revenues to reduced procurement orders from U.S. government
DEVELOPMENT FUNDING - Co secured $27 mln in additional U.S. government funding for development activities in 2025

Company press release: ID:nGNX3WGZVj

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY EPS		$0.32
FY Net Income		$23.3 mln

Analyst Coverage

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618896602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-11 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618896602","market":"nz","top_or_hot":-1,"title":"SIGA Technologies 2025 revenue falls","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>SIGA Technologies 2025 revenue falls</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. infectious disease drugmaker's 2025 revenue and net income fell sharply from prior year</p></li><li><p>In January 2026, company received $13 mln international order for oral TPOXX</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA received $13 mln international procurement order for oral TPOXX to be delivered in 2026</p></li><li><p>Company expects CHMP to confirm positive benefit-risk balance for tecovirimat in March 2026</p></li><li><p>SIGA focused on securing new procurement contracts with governments to support future revenues</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. PROCUREMENT DROP - Co attributed lower 2025 revenues to reduced procurement orders from U.S. government</p></li><li><p>DEVELOPMENT FUNDING - Co secured $27 mln in additional U.S. government funding for development activities in 2025</p></li></ul><p>Company press release: <span>ID:nGNX3WGZVj</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY EPS</p></td><td></td><td><p>$0.32</p></td><td></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>$23.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIGA Technologies 2025 revenue falls</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIGA Technologies 2025 revenue falls\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-11 04:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>SIGA Technologies 2025 revenue falls</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. infectious disease drugmaker's 2025 revenue and net income fell sharply from prior year</p></li><li><p>In January 2026, company received $13 mln international order for oral TPOXX</p></li></ul><p><span>Outlook</span></p><ul><li><p>SIGA received $13 mln international procurement order for oral TPOXX to be delivered in 2026</p></li><li><p>Company expects CHMP to confirm positive benefit-risk balance for tecovirimat in March 2026</p></li><li><p>SIGA focused on securing new procurement contracts with governments to support future revenues</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>U.S. PROCUREMENT DROP - Co attributed lower 2025 revenues to reduced procurement orders from U.S. government</p></li><li><p>DEVELOPMENT FUNDING - Co secured $27 mln in additional U.S. government funding for development activities in 2025</p></li></ul><p>Company press release: <span>ID:nGNX3WGZVj</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY EPS</p></td><td></td><td><p>$0.32</p></td><td></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>$23.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SIGA","symbol_name":"SIGA Technologies Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL1N3ZY15P:1","article_id":"2618896602","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618896602","pubTimestamp":1773173517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SIGA Technologies 2025 revenue fallsOverviewU.S. infectious disease drugmaker's 2025 revenue and net income fell sharply from prior yearIn January 2026, company received $13 mln international order fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SIGA":"SIGA Technologies Inc","BK4583":"猴痘概念","BK4007":"制药"},"translate_title":"SIGA Technologies 2025年收入下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SIGA":0.9},"content_text":"SIGA Technologies 2025 revenue fallsOverviewU.S. infectious disease drugmaker's 2025 revenue and net income fell sharply from prior yearIn January 2026, company received $13 mln international order for oral TPOXXOutlookSIGA received $13 mln international procurement order for oral TPOXX to be delivered in 2026Company expects CHMP to confirm positive benefit-risk balance for tecovirimat in March 2026SIGA focused on securing new procurement contracts with governments to support future revenuesResult DriversU.S. PROCUREMENT DROP - Co attributed lower 2025 revenues to reduced procurement orders from U.S. governmentDEVELOPMENT FUNDING - Co secured $27 mln in additional U.S. government funding for development activities in 2025Company press release: ID:nGNX3WGZVjKey DetailsMetricBeat/MissActualConsensus EstimateFY EPS$0.32FY Net Income$23.3 mlnAnalyst CoverageThe stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months agoFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618896602","isCrawlerRequest":true}